DelMar Pharmaceuticals Provides Update on VAL-083 Glioblastoma Clinical Trial February 26, 2014 • 8:00 AM EST
DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com December 9, 2013 • 8:00 AM EST
DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com December 5th December 2, 2013 • 4:11 PM EST
DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting November 22, 2013 • 8:00 AM EST
DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology November 14, 2013 • 8:00 AM EST
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers October 21, 2013 • 8:00 AM EDT
DelMar Pharmaceuticals to Present at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting October 15, 2013 • 8:00 AM EDT
DelMar Pharma talks to Life Sciences IP Review (LSIPR) about creating new patents for shelved drugs to streamline path to patients October 9, 2013 • 8:00 AM EDT
DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV September 19, 2013 • 8:00 AM EDT
DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com September 16, 2013 • 12:09 PM EDT